Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?

(2011) Magnus Gisslén et al.   BMC INFECTIOUS DISEASES

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA

(2011) N. Clumeck et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cost-Efficacy Analysis of the MONET Trial Using UK Antiretroviral Drug Prices

(2011) Brian Gazzard et al.   Applied Health Economics and Health Policy

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

(2010) Ana Canestri et al.   CLINICAL INFECTIOUS DISEASES

Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy

(2010) Aylin Yilmaz et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment

(2010) Arvid Edén et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

(2010) R. K. Heaton et al.   NEUROLOGY

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

(2010) Lars Hagberg et al.   AIDS Research and Therapy

Validity of the CogState Brief Battery: Relationship to Standardized Tests and Sensitivity to Cognitive Impairment in Mild Traumatic Brain Injury, Schizophrenia, and AIDS Dementia Complex

(2009) P. Maruff et al.   ARCHIVES OF CLINICAL NEUROPSYCHOLOGY